AZ to promote Luye's locally developed CV drug in China

China's Luye Pharma Group Ltd. (HKEX:2186) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) exclusive rights to promote Luye's blood lipid regulator Xuezhikang in mainland China.

Read the full 230 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE